/

GOVX

GeoVax Labs, Inc.Pre-market

0.2656−0.02 −5.92%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayPre-market 0.2656 0.00%

Open

0.2823

Prev close

0.2823

Day range

0.26540.2861

52-week range

0.265415.75

Volume

226.24K0.29×

Mkt cap

2.68M

P/E ttm

—

Fwd P/E

-0.31

EPS ttm

-8.84

Div yield

0.00%

Earnings

—

From 52w high

−98.31%

Price Chart

Yahoo Finance · delayed

GOVXOct 13, 2026O 0.2820H 0.2860L 0.2600C 0.2660−0.0160 (−5.67%)Vol 226.20K

SMA 500.5073
SMA 2001.5265

1Y change −98.09% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

GOVX GeoVax Labs, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.96%
1 month: −42.55%
3 months: −74.67%
6 months: −80.15%
Year to date: −93.78%
1 year: −98.09%

Valuation & ownership

Market cap: 2.68M
Enterprise value: −863.01K
P/E (ttm): —
Forward P/E: -0.31
PEG ratio: —
Price / book: 1.11
Price / sales (ttm): —
EV / EBITDA: 0.04
EPS (ttm): -8.84
EPS (forward): -0.8600
Beta (5y monthly): 3.69
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 10.10M
Float: 6.92M
Short % of float: 2.79%
Short ratio (days): 0.89
Held by insiders: 0.03%
Held by institutions: 9.77%
Avg volume (3m): 778.92K
50-day average: 0.5165
200-day average: 1.55
52-week change: −98.09%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 18.2
vs 50-day SMA: −47.57%
vs 200-day SMA: −82.57%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 16.20%
Realised vol (20d, ann.): 54.8%
From 52-week high: −98.31%
From 52-week low: +2.31%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

10.00

+3,665.06% implied

Low 10.00Median 10.00High 10.00

Recommendation trend

Now2 / 0 / 0
1m ago2 / 0 / 0

Buy / hold / sell counts

Recent actionsAll (UPDN) →

DES

About GeoVax Labs, Inc.

Yahoo Finance profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Sector: Healthcare
Industry: Biotechnology
Employees: 19
Headquarters: Smyrna, GA, United States
Website: geovax.com
Officers: Mr. David Alan Dodd Chairman, President & CEO
Dr. Mark J. Newman Ph.D.

SEAS

Seasonality · GOVX

2020–2026 · monthly returns

Strongest month Jul +33.72%Weakest month Sep −26.59%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-34.5	-42.9	-13.8	-21.0	89.0	-38.3	-46.4	-7.2	-47.2	-20.5			−93.8%
2025	-22.7	-24.6	-26.4	-4.7	1.0	-15.1	-16.9	3.6	-36.6	19.7	-27.4	-58.4	−93.1%
2024	-38.5	-23.1	-21.9	-30.0	30.0	75.0	-34.7	122.6	-47.9	-18.3	34.0	-6.4	−54.4%
2023	28.4	-16.9	-1.0	-7.1	0.3	-11.3	3.8	1.1	-10.9	-3.7	-13.3	-15.9	−42.7%
2022	-33.1	-26.9	-35.0	-31.3	122.8	-52.8	228.9	-56.4	-8.4	-13.8	-15.5	-20.7	−82.6%
2021	38.5	9.0	-14.1	24.2	-0.4	-7.7	-12.6	39.4	-29.1	-3.2	-1.2	-12.3	+7.1%
2020										-8.5	-0.7	16.6	+6.0%

INSD

Insider Activity · GOVX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Oct 16, 2025	Spencer John N JrDirector	Purchase at price 0.55 per share.	10K	$5.50K
Aug 6, 2025	Mckee Kelly T Jr.Officer	Purchase at price 0.67 per share.	1.1K	$742
Apr 9, 2025	Spencer John N JrDirector	Purchase at price 0.98 per share.	10K	$9.80K
Apr 9, 2025	Sharkey John W Ph.D.Officer	Purchase at price 0.99 per share.	6K	$5.94K
Mar 31, 2025	Dodd David AChief Executive Officer	Purchase at price 1.08 per share.	10K	$10.80K
Mar 30, 2025	Reynolds Mark WChief Financial Officer	Purchase at price 1.08 per share.	6.8K	$7.34K

GOVX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

GOVX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About GeoVax Labs, Inc.

Seasonality · GOVX

Insider Activity · GOVX

Congress Trades · GOVX

Investors Holding GOVX

Investors Holding GOVX

Congress Trades · GOVX

Insider Activity · GOVX

Seasonality · GOVX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About GeoVax Labs, Inc.

Financial Snapshot

Earnings & Dividends

News